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ABSTRACT

INFLUENCES OF ANTROQUINONOL AND 4-ACETYLANTROQUINONOL B ON
INFLAMMATORY TUMORIGENESIS IN THE MCF-7 BREAST CANCER CELL
LINE WITH OR WITHOUT TNF-α STIMULATION
SEPTEMBER 2018
TING-CHUN LIN, B.S., TAIPEI MEDICAL UNIVERSITY, TAIWAN
M.S., UNIVERSITY OF MASSACHUSETTS, AMHERST
Directed by: Dr. Zhenhua Liu

Breast cancer (BC) is one of the most common cancers among women worldwide that
~25% of new cancer cases diagnosed every year would be BC; moreover, ~15% of cancer
deaths per year caused by BC makes it the leading cause of cancer death among women
worldwide. To date, though the cause of a large proportion of BC are still unclear, recent
studies have revealed that a supportive breast tissue microenvironment is critical for the
development and progression of BC, especially the communication with immune cells
within breast tissue. Therefore, breast inflammatory microenvironment is currently
received a substantial attention in the prevention and treatment of BC. Research on breast
cancer immunology suggests that inflammatory mediators, estrogen and several
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inflammation-related tumorigenic pathways are potentially contributors for inflammatory
breast tumorigenesis. It is evidenced that elevated levels of inflammatory mediators, such
as cytokines, chemokines, prostaglandins, and enhanced estrogen production while
suffering from chronic inflammation is responsible for not only activating oncogenic
pathways, for example NF-κB, STAT3 and Wnt signaling pathways, but also reducing the
efficacy of cancer-specific immunity against tumor cells. Accordingly, targeting the
chronic inflammatory status in breast tissue has become a promising strategy for breast
cancer therapy. Recently, due to the annoying side effects accompanying by traditionally
anticancer drugs, there is an increased interest in finding out natural sources to treat BC.
Herein, we report that antroquinonol (AQ) and/or 4-acetylantroquinonol B (4-AAQB)
isolated from Antrodia Camphorata were able to modulate the expression of several
inflammatory mediators, IL-6 and IFN-γ in particular, and downregulate the aromatase
expression and Wnt signaling responses induced by inflammatory status. Taken together,
the present findings provide new insights into the role of AQ and 4-AAQB in inflammatory
breast tumors and also suggest them as promising candidates for breast cancer
immunotherapy.
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CHAPTER 1
INTRODUCTION

Recent studies have indicated that within a tumor microenvironment (TME), tolerant
immune responses involved in innate and adaptive immune systems play key roles in
cancer progression (Wang et al., 2004). Prolonged and enhanced inflammatory activity
caused by different conditions, such as microbial infections, chemicals exposures,
autoimmune diseases and obesity, would lead to chronic, “smoldering” and low-grade
inflammation (Balkwill et al., 2005; Mantovani et al., 2008; Divella et al., 2016). It is now
evidenced that several immunosuppressive cells that are responsible for tolerant immunity
including regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSCs) are often
found in breast tumors (Jiang et al., 2014). These cells along with soluble molecules could
induce an immunosuppressive microenvironment predisposing breast tumor development.

Recently, duo to the various side effects of anti-cancer drugs, research on complementary
and alternative medicine (CAM), which is used to help patients lessen side effects and
discomfort following conventional medicine, has risen in scientific community. According
to 2012 national health interview survey, 33.2% of US adults used CAMs, and the most
common CAM for cancer treatment in United States was the use of natural products (17.7%
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of adults), some of which possess a variety of phytonutrients with potential benefits to
human health (NHIS, 2012). Among these natural products, mushrooms have been
considered as one of the most powerful functional foods for preventing and treating cancer
via their effective anti-cancer and immunomodulatory effects (Valverde et al., 2015).

Antrodia Camphorata (AC) as one of the medicinal mushrooms used in traditional
Taiwanese medicine has been reported to possess diverse health-promoting effects in
modern medicine, such as anti-microbial, anti-hepatitis B virus, anti-oxidant and especially
anti-cancer and immunomodulatory effects, attributed to the various nutraceuticals found
in AC (Geethangili et al., 2011; Lien et al., 2014). Two recently isolated compounds,
antroquinonol (AQ) and 4-acetylantroquinonol B (4AAQB), from AC mushrooms emerge
as promising anti-cancer drug candidates. Experiments conducted in various cancers
demonstrated the roles of AQ and 4-AAQB in diverse anti-cancer properties such as antiproliferation (Kumar et al., 2011; Lin et al., 2011), pro-apoptosis (Yu et al., 2012), antiinvasion and metastasis (Thiyagarajan et al., 2015; Lee et al., 2015) and anti-cancer
stemness (Chang et al., 2015; Lin et al., 2017). However, the effects of these compounds
on anti-tumor immunity in breast cancer (BC) remain unclear. Our present study aims to
understand how AQ and 4-AAQB modulates mammary inflammatory microenvironment,
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aromatase, an enzyme responsible for a key step in the biosynthesis of estrogens in women,
as well as tumorigenic Wnt pathway related genes in MCF-7 BC cells.

3

CHAPTER 2
LITERATURE REVIEW

2.1 Breast Cancer

BC is the most common cancer in women worldwide. Nearly 1.7 million new BC cases
were diagnosed in 2012, representing about 25% of all types of cancers in women (Ferlay
et al., 2015). BC, with a standardized mortality rate of 12.9 per 100,000, is the second
highest cause of cancer death (Ghoncheh et al., 2016). In the United States, about 12% of
women, that is 1 in 8 women, will be diagnosed with invasive BC during their lifetime.
Despite the incidence and death rates of BC in the US are both gradually decreasing for the
past two decades, BC death rates are still higher than any other cancer, besides lung cancer
(DeSantis et al., 2014).

In general, based on molecular subtypes, BC can be divided into mainly three categories:
hormone receptor-positive BC, HER2 protein-positive BC and triple-negative BC (TNBC).
Hormone receptor-positive BC is the major type among these three, and includes estrogen
receptors (ER)-positive and/or progesterone receptors (PR)-positive BC, accounting for
~70% of human BC (Spears et al., 2009). TNBC, which is ER-negative, PR-negative and
HER2-negative, is the most complex one, since it is not the hormones that facilitate cancer
4

cell growth, and currently, there is no targeted therapy specifically for its treatment (Reddy
et al., 2011). Since BC in women is prevalent worldwide, particularly in the industrialized
countries, and current treatments, including surgery combined with chemotherapy,
radiation and hormone therapy, have significant side effects, it is highly attractive to
develop dietary strategies, e.g. identifying natural medicinal compounds that have
preventive or chemopreventive capability for reducing BC risk with less adverse effects.

The cause of BC is complex and may attributes to several risk factors related to age, family
history of breast and other cancers, endogenous and exogenous hormone exposure, and
environmental and lifestyle changes. About 5 to 10% of BCs are associated with hereditary
gene mutations, and among them more than 50% of the inherited cases can be directly
linked to BRCA1 and/or BRCA2 gene mutations (Ford et al., 1998; Slavin et al., 2017).
Other factors, such as sex hormone, exposures to environmental chemicals and pollutants,
obesity, dietary factors, alcohol and tobacco are responsible for the majority of BC (Chen,
2008; Hiatt et al., 2018). By understanding the causation between these risk factors and
BC, researchers and health promotion practitioners can develop effective strategies or
policy against BC in both prevention and therapy levels.

Overview the history of BC therapy strategies, researchers tend to focus their studies on
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tumor cell-intrinsic factors such as genetic, epigenetic properties and biology of tumor cell
per se. However, recent development of cancer intervention has shifted the topics toward
the whole TME (Williams et al., 2016). In fact, in 1889 Stephen Paget had already proposed
a “Seed and soil” theory for cancer development suggesting that tumors can only be formed
by neoplastic cells with a favorable and supportive environment (Paget, 1989). In general,
breast TME is composed of tumor cells, stromal cells, adipocytes, immune cells, as well as
various extracellular molecules, such as cytokines, chemokines, and growth factors,
secreted by tumor cells and surrounding cells (Place et al., 2011; Huang et al., 2017) (Figure
1). Within a breast TME, immune cells, especially macrophages, play critical roles in the
development and progression of BC (Ward et al., 2015). Therefore, breast inflammatory
microenvironment is currently received substantial attention in the prevention and
treatment of BC.
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Figure 1. Breast tumor microenvironment
2.2 Inflammatory Microenvironment and Breast Cancer

The first connection between inflammation and cancers can be traced back to 19th century,
Rudolf Virchow noted that infiltrated leukocytes present within tumor tissue, and
hypothesized that “lymphoreticular infiltrate reflected the origin of cancer at sites of
chronic inflammation” (Balkwill et al., 2001). Indeed, though this idea has been
undervalued more than a century, the shift of recent cancer research from tumor cells to the
TME uncovers myriad solid evidence that describe the interaction between immune cells
and tumor cells in the microenvironment.
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Evidence has clearly indicated that chronic inflammation with elevated serum levels of
tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP)
caused by obesity or other inflammatory conditions are associated with increased BC risk,
and may play an important role in tumorigenesis (Agnoli et al., 2017). Additional evidence
is the use of anti-inflammatory drugs such as nonsteroidal anti-inflammatory drugs
(NSAIDs), e.g. COX2 inhibitors, aspirin, ibuprofen and other NSAIDs, steroidal antiinflammatory drugs, e.g. corticosteroids, and anti-cytokine and chemokine drugs, e.g. antiIL-6, anti-TNF-α, and anti-CXCR4 drugs in cancer therapy, and these drugs have been
shown to be beneficial for reducing cancer incidence, improving therapy, and decreasing
mortality from cancers, including BC (Harris et al., 2003; Rayburn et al., 2009;
Grivennikov et al., 2010). These findings supported Virchow’s hypothesis, reemphasized
the importance of inflammation toward cancer progression, and significantly encouraged
the research involved in cancer immunology and its implications for cancer prevention and
therapy.

The key factors contributing to the adverse effects of inflammation on breast cancer are
transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB) and signal transducer and activator of transcription 3 (STAT3), and related
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inflammatory cytokines such as TNF-α, IL-6 and IL-1β (Mantovani et al., 2008). In the
inflammatory microenvironment, neoplastic cells, adipocytes, stromal cells and immune
cells are all under an inflammatory status through a positive feedback loop between
transcription factors and their targeted inflammatory mediators. Therefore, the influence of
the various inflammatory molecules that secreted from all types of cells in the
microenvironment play critical roles in breast tumorigenesis and tumor progression.

2.2.1 Inflammatory Cytokines

TNF-: In an inflammatory microenvironment, the inflammatory cytokines, particularly
TNF-α, IL-1β and IL-6 are most extensively studied. TNF-α was originally identified to be
a cytokine inducing cell lysis, especially tumor cells (Locksley et al., 2001). Later research
discovered a wide range of effects of chronic, low dose TNF-α on tumor cells in the aspects
of cell proliferation, survival, differentiation, anti-apoptosis, angiogenesis, epithelial–
mesenchymal transition (EMT) as well as inflammatory responses (Dempsey et al., 2003;
Balkwill et al., 2009), which are mainly through the activation of NF-κB inflammatory
pathway (Wang et al., 2008; Hoesel et al., 2013). Eftekhari et al. (2017) indicated that in a
breast TME, TNF-α expression level is gradually increasing and parallel with the breast
tumor stage. To date, several studies have demonstrated the role of TNF-α in inflammation-
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related cancers. Moore et al. (1999) showed that TNF-α knockout mice is resistant to skin
carcinogenesis caused by inflammation. In addition, Oshima et al. (2005) pointed out that
the inhibition of TNF-α related inflammation is capable of suppressing gastric tumor
progression in transgenic mice induced by cyclooxygenase-2 (COX2) and microsomal
prostaglandin E synthase-1 overexpression. The pro-tumor effects of TNF-α and TNF-α
induced other cytokines, chemokines and prostaglandins (PGs) may attribute to their acts
on different cell types in the whole TME that eventually skew it to a tumor friendly
environment (Balkwill, 2009).

IL-1β: Similar with TNF-α, IL-1β is capable to activate NF-κB and AP-1 by binding with
IL-1 receptors and/or toll-like receptors, promoting tumor cell survival, proliferation,
metastasis, tumor angiogenesis (Divella et al., 2016). IL-1β in a TME is shown to be
responsible for the recruitment of COX-2-expressing leukocytes and the promotion of
inflammatory angiogenesis caused by upregulating angiogenic factors such as
prostaglandin E2 (PGE2), vascular endothelial growth factor, CXC chemokines, and matrix
metalloproteinases (MMPs) (Nakao et al., 2005). Escobar et al. (2015) also indicated that
IL-1β highly expressed by metastatic ER negative BC cell, MDA-MB-231, is able to
stimulate the secretion of chemokines related to aggressive metastasis by mesenchymal
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stem cells in a co-culture cell model.

IL-6: IL-6 is a pro-inflammatory cytokine that is regulated by NF-κB pathway and is also
a key modulator in cancer-related inflammation (Divella et al., 2016). IL-6 is the major
activator of STAT3 transcription factor, which is responsible for the expression of genes
related to pro-proliferation, anti-apoptosis, tumor metastasis, angiogenesis, and
immunosuppression (Yu et al., 2009). Moreover, the activation of STAT3 in various
immune cells is able to promote the maturation of immunosuppressive cells such as tumorassociated macrophages (TAMs), MDSCs, Treg cells and T helper 17 (TH17) cells, whereas
reduce the stimulation of tumor cytotoxic cells such as TH1 cells and cluster of
differentiation (CD) 8+ T cells (Yu et al., 2009). Recent studies of IL-6 in BC have point
out its pro-tumor effects and association with poor patient outcomes (Salgado et al., 2003;
Won et al., 2013).

Other inflammatory cytokines: Other proinflammatory cytokines, such as interferon-γ
(IFN-γ), IL-10 and transforming growth factor-β (TGF-), is also widely studied in cancer
immunology field. 1) IFN-γ is regulated by transcription factor NF-κB, and would
stimulate JAK/STAT1 signaling pathway. The role of IFN-γ in cancer-related inflammation
is a two-faced factor in terms of pro- and anti-tumor effects. In the tumor initiation stage,
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IFN-γ can protect normal cells from damage, whereas during this process, it may lead to
the accumulation of oncogenic mutations, resulting in potent cancer cell transformation
(Zaidi et al., 2011). 2) IL-10 in immunology is generally known as an anti-inflammatory
cytokine, but its effects in the pathogenesis of cancer is still controversial. Evidence has
suggested that IL-10 signaling alone or co-stimulation with other cytokines such as IL-2 or
IL-4 can activate either STAT3 or STAT1 according to in vitro or in vivo studies (Mannino
et al., 2015). Since STAT3 and STAT1 activation is responsible for immunosuppression
and immunostimulation respectively, IL-10 may serve as pro-tumor or anti-tumor factor
depending on the existence microenvironment. 3) TGF-β also has two-faced property
toward tumor development. In normal cells, TGF-β serving as a tumor suppressor protein
can protect cells from tumor cell transformation through cell cycle inhibition, induction of
apoptosis and inhibition of cell immortalization (Lebrun, 2012). However, elevated TGFβ secreted from tumor cells, stromal cells and immune cells in a TME can promote tumor
cell progression and metastasis. In addition, TGF-β in a TME can positively contribute to
tumor immunosuppression by directly or indirectly weaken function of cytotoxic T and B
lymphocytes against tumor cells, allowing tumors to evade from immunosurveillance (Yu
et al., 2009; Lebrun, 2012).
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2.2.2 Chemokines

Chemokines are another group of molecules that are elevated in an inflammatory
environment, particularly obesity-associated inflammation. Chemokines and chemokine
receptors also play important roles in terms of their signaling greatly regulating tumor cell
migration and invasion and immune cell infiltration (Figure 2). Given the phenomenon of
immune cell infiltration in a TME, various inflammatory mediators upregulate the
expression of chemokines and chemokine receptors in immune cells as well as tumor cells.
Müller et al. (2001) found that in breast tumor cells, C-C motif chemokine receptor 7
(CCR7) and C-X-C motif chemokine receptor 4 (CXCR4) are highly expressed compared
to normal mammary epithelial cells in vitro and in vivo. Similar with the mechanisms
involved in lymphocyte trafficking, chemokine signaling also triggers actin polymerization
in breast tumor cells in order to form pseudopod and move the cells forward, resulting in
tumor cell migration and invasion to distal metastatic niches with high levels of chemokine
ligands C-C motif chemokine ligand 21 (CCL21) and C-X-C motif chemokine ligand 12
(CXCL12). On the other hand, chemokines acting as chemoattractants can attract immune
cell infiltrating to tumor site, such as CCL2 (monocyte chemoattractant protein 1, MCP1)-mediated macrophage recruitment in BC, and through the cytokines and chemokines
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interaction between macrophages and tumor cells, it can further promote the maturation of
tumor-associate macrophages (TAMs) and metastatic tumor cells favorable for tumor
immune evasion, tumor angiogenesis and metastasis (Stewart et al., 2012; Tariq et al.,
2017).

Figure 2. Elevated expression of chemokines & chemokine receptors promote metastatic
breast cancer
2.2.3 Cyclooxygenase-2 and Prostaglandins

The links between cyclooxygenase (COX; also known as prostaglandin-endoperoxide
synthase, PTGS) and inflammation can be traced back to the first discovery of NSAIDs in
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the early 1970. They were shown to be able to mitigate inflammation by inhibiting PGs
synthesis mediated by enzyme COX. Moreover, the later research on COX revealed that
its increased activity is correlated to the inflammatory status, and could be induced by
inflammatory cytokines and endotoxins (Seibert et al., 1994). There are two COX isozymes
found in human body, including COX-1 and COX-2. COX-1 is normally existed and
constitutively activated in various tissue to maintain physiological functions, for example
gastrointestinal, renal, endothelium protection and platelet aggregation, whereas, COX-2
is almost silent in normal tissue and is inducible only in the context of inflammatory stage,
including cancer-related inflammation. Recently, studies have pointed out that COX-2 is
upregulated or overexpressed in various types of cancers, such as oral, gastric, bile duct,
colorectal, head and neck, skin, prostate, breast, liver, pancreatic, bladder, lung, ovarian,
and cervical cancers (Koki et al., 2002).

The main function of COX-2 pathways is to produce prostanoids, including thromboxane
and PGs, from enzymatically conversion of arachidonic acids (Smyth et al., 2009). PGs
involve in various physiological functions in human body such as vasodilation,
bronchodilation, muscle contraction, platelet aggregation; moreover, they can greatly
contribute to advanced inflammation and tumor progression, especially PGE2. Several
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molecular pathway involved in inflammation and tumor development directly target COX2 promoter, including NF-κB, STAT3 and MAPK pathways (Xiong et al., 2014; Desai et
al., 2018), and by upregulated COX-2 expression and increased production of PGE2, a
positive feedback loop can be generated between these pathways and COX-2 pathway,
further exacerbating the inflammation and tumor progression (Lin et al., 2015; Aoki, 2015).
In general, constitutive COX-2 activation and PGE2 production can potentially promote
both the initiation of breast tumorigenesis and later progression through a variety of
pathways (Harris et al., 2014; Galván et al., 2017).

2.2.4 Immune Checkpoints

Recently, research on the interaction between cancer cells and immune cells in terms of
effects on escaping from immunosurveillance is quite promising for cancer immunotherapy.
During inflammation, immune checkpoints, serving as regulators of various immune cell
activation, are key factors for maintaining self-tolerance, which represents the ability for
immune system to correctly identify and target foreign antigens instead of autoantigens,
avoiding autoimmune responses and tissue damage. Generally, anti-tumor immunity can
be referred to a cancer-immunity cycle with several steps, including a) releasing of cancer
cell antigens, being captured by antigen-presenting cells (APCs), and presenting cancer
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antigen to T cells by APCs; b) activating effector T cells (Teff) against cancer cells, Teff
trafficking to tumor site, and infiltrating into tumor; c) recognizing cancer cells by binding
cancer antigen with T cell receptor, killing cancer cells, and releasing additional cancer
antigens (Chen et al., 2013). In the process of cancer-immunity cycle, the activation of Teff
would be the key step to initiate effective tumoricidal function of anti-tumor immunity. T
cell activation is not merely regulated by interaction between cancer-associated antigens
and T cell receptor, but also may co-regulated with other ligands and receptor proteins
presented on the surface of APCs and tumor cells. These proteins can be divided into two
categories, positive and negative regulators, responsible for co-stimulating or co-inhibiting
Teff function respectively (Topalian et al., 2015), and between these two membrane proteins,
negative regulators are referred to immune checkpoints.

However, this host defense mechanism is dysfunction within a TME, resulting in evasion
of tumor immunosurveillance (Pardoll, 2012). For instance, recent findings suggest that
CD47 as a pro-phagocytic signal is commonly upregulated in various tumor cells including
breast tumor (Manna et al., 2004; Chao et al., 2011), possibly through dysregulated NF-κB
and HIF-1 pathways (Lo et al., 2015; Zhang et al., 2015; Betancur et al., 2017), and
increased expression of CD47 could specifically engage with its receptor signal regulatory

17

protein α (SIRPα), generating “don’t eat me “ signals to macrophages (McCracken et al.,
2015) (Figure 3). By blocking CD47-SIRPα signal with CD47 antibody or CD47
knockdown, macrophage-mediated phagocytosis of tumor cells is retrieved (Bener et al.,
2016; Liu et al., 2017).

Figure 3. Activated CD47 signaling toward macrophage disrupts macrophage
phagocytosis of breast cancer and the following T cell immunity activation
2.3 Chronic Inflammation and the Estrogen Mechanisms

Hormone receptor-positive cancer is the major type of BC, with approximately 70% of
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human BCs depending on hormones and the expression of their receptors (Spears et al.,
2009). Reproductive issues such as ages at menstruating, first birth and menopause as well
as the use of hormone replacement therapy for menopause symptoms and oral
contraceptives are all established factors for BC via hormonal mechanisms (Chen, 2008).
Although it is still in its infancy, researches have demonstrated the interplay between
inflammation and hormones. The sex hormones appear to have important, but complex
effects on the body’s inflammatory response. For example, many observers have wondered
if the increase in inflammatory diseases that coincide with menopause, such as arthritis,
might be related to shifts in the balance of progesterone and estrogens, and thereby
hormones may contribute to breast tumorigenesis via the inflammatory response. However,
estrogens, by themselves, directly promotes tumorigenesis via through immunomodulatory
effects and chronic inflammation, in fact may also contribute to the development of BC via
hormonal pathways (Amadou et al., 2013; Quigley et al., 2017).

2.3.1 Pro-tumor Immunomodulatory Effects of Estrogen

It is the fact that the susceptible of infection and related mortality for women are generally
lower, whereas the susceptible of autoimmune disease is higher, than men, and one of the
underlying factor contributing to this difference is suggested to be female sex steroid
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hormone, which is capable of interacting with immune system (Grossman, 1985). The
immunomodulatory effects of estrogen are two-faced, including immunosuppression and
immunostimulation, and its effects on immune function seem to be extensively dependent
on estrogen concentration, composition of estrogens and targeted cell types (Straub, 2007).
In a TME, various cell types, such as tumor cells, stromal cells as well as immune cells,
secret aromatase and estrogen, and via autocrine and/or paracrine estrogen pathways, these
hormones may promote tumor progression by weakening anti-tumor immune responses
(Rothenberger et al., 2018). Estrogen is suggested to have the ability to induce tumoricidal
M1 macrophage polarization toward immunosuppressive M2 in a TME (Gilliver, 2010;
Svensson et al., 2015). Moreover, evidence indicates that estrogen can increase the
accumulation of MDSCs in tumors and enhance their immunosuppressive activities by
estrogen receptor-mediated upregulation of STAT3 signaling (Svoronos et al., 2017);
influence CD4+ helper T cell differentiation, APCs functions and chemokines production,
by which would lead to increased TH2 cytokines production such as IL-4 and IL-10,
decreased cell-mediated TH1 immune response and impaired T cell activation (Salem,
2004); stimulate Tregs activation (Tai et al., 2008); increase T cell anergy (Polanczyk et al.,
2007; Yang et al., 2017); inhibit cytotoxic T lymphocyte- and NK cell-mediated apoptosis
against tumor cells (Jiang et al., 2006). Above-mentioned immunosuppressive effects of
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estrogen on both innate and adaptive immune system could converge to pro-tumor
immunity, creating a tumor friendly microenvironment and promoting cancer progression.

2.3.2 Aromatase as a Mediator Between Inflammation and Breast Tumorigenesis

Since epidemiological studies have indicated that obesity or adiposity and its underlying
chronic inflammatory status are associated with BC risk in post-menopausal women (Rose
et al., 2010), the interaction and related molecular mechanisms among obesity,
inflammation and BC have been intensively investigated, and the increased proinflammatory mediators within mammary adipose tissue are proposed as critical cellular
mechanisms (Rose et al., 2015). In an obese state, large number of macrophages infiltrate
into adipose tissue, typically being around individual adipocytes to form a “crown-like
structure” (CLS), which is a representative feature of adipose tissue inflammation and
simultaneously serve as a major contribution to proinflammatory cytokines such as TNFα, IL-6 and chemokine MCP-1. The mediators secreted from CLS can further recruit
additional monocytes and lymphocytes, in turn deteriorating the inflammatory process
(Rose et al., 2015; Cowen et al., 2015).

In addition to direct effects of inflammatory cytokines in the modulation of tumorigenic
pathways

as

described

in

previous
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sections

of

this

review,

an

obesity→inflammation→aromatase axis is present in the breast tissue of most overweight
and obese women (Morris et al., 2011; Rose et al., 2015; Cowen et al., 2015). In
postmenopausal women, estrogen production is mainly from enzymatic conversion of
androgen (androstenedione) into estrogen (estrone) in the adipose tissue instead of the
ovaries, which are the main sources of estrogen production in premenopausal women, and
the responsible key enzyme is called aromatase (cytochrome P450 19A1, CYP19A1). In
an obese state, the increased numbers of CLS, enhanced activation of the NF-κB
transcription factor (Hursting, 2011; Zahid et al., 2016), and increased secretion of
inflammatory mediators, such as IL-6 (Reed et al., 1992), TNF-α (Zhao et al., 1996), IL11, leukemia inhibitory factor, oncostatin M, insulin-like growth factor 1 (IGF-1) (Zhao et
al., 1995) and PGE2 (Richards et al., 2003), are directly associated with elevated aromatase
levels and activity in the mammary glands (Figure 4). The inflammation-aromatase axis
indicates a hormonal mechanism between inflammation and breast tumorigenesis.
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Figure 4. Elevated levels of inflammatory mediators during chronic inflammation
stimulate aromatase expression and activity
2.4 Inflammation and Breast Cancer: The Wnt-Signaling Pathway Connection

While chronic inflammation plays a critical role in breast tumorigenesis, inflammatory
mediators-induced oncogenes expression also greatly involves in this causality, for
instance, the secretion of Wnt proteins and triggered signalings are one of the major
oncogenic pathways.

2.4.1 Wnt-Signaling Pathway and Breast Cancer

The discovery of Wnt protein is first proposed with the term “Int-1” (integration 1) by Roel
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Nusse and his colleagues (1984) in the light of a research on mouse mammary tumour virus
(MMTV) infected mice and the oncogene correlated to following breast tumorigenesis.
However, the identification of this gene was actually characterized as swaying and wingless
(Wg) previously in both mouse and drosophila models respectively with the functions
involved in embryonic development such as cell proliferation, differentiation, and polarity
(Nusse, 2005; Klaus et al., 2008). Due to the multiple names of this gene and its related
genes, researchers renamed these gene family as Wnt family standing for the blend of Wg
and Int (Klaus et al., 2008). Similar with other molecular mechanisms involved in
embryonic development, mutations appeared in these pathways or their inhibitors would
lead to dysregulation of cell growth and motility control, resulting in tumorigenesis. Recent
studies have indicated that Wnt family in human comprises 19 proteins, and as ligands there
are three signaling pathways, one canonical and two non- canonical pathways, could be
activated by binding Wnt proteins to corresponding receptors and co-receptors, frizzled
receptor family and low-density lipoprotein-related protein 5/6, respectively (Komiya et
al., 2008).

The canonical pathway, also known as Wnt/β-catenin pathway, is thought to be the major
signaling contributing to oncogenesis. Due to the receptors binding of Wnt protein,
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increased β-catenin accumulates in the cytoplasm, eventually translocating into nucleus
and acting as a coactivator of T-cell factor/lymphoid enhancer factor transcription factors
for upregulating Wnt targeted genes expression (Nusse, 2005), such as c-myc, axin-2, and
cyclin D1, some of whom are responsible for regulating critical cell functions, cell survival,
stem cell renewal and organogenesis for example (Komiya et al., 2008). The other two
signalings are β-catenin independent pathways, including planar cell polarity pathway and
the Wnt/Ca2+ pathway, of which’s role is primarily in regulating cell motility and polarity
and Ca2+-dependent cellular signaling via the activation of protein kinase C (PKC) and
Ca2+/calmodulin-dependent protein kinase II (CaMKII) (Seifert et al., 2007; De, 2011).
Furthermore, recent studies show that Wnt5a might serve as a tumor suppressor gene via
the stimulation of Wnt/Ca2+ pathway to block Wnt/β-catenin pathway through CaMKIImediated and calcium-sensing receptor-mediated β-catenin phosphorylation and increasing
β-catenin degradation in thyroid and colon carcinoma, respectively (Kremenevskaja et al.,
2005; MacLeod et al., 2007).

Wnt/β-catenin pathway activation is commonly found in various cancer types, and most of
the dysregulations of this pathway can be attributed to genetic mutations on signalingrelated genes, posttranslational modification of key regulators as well as the
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downregulation of Wnt antagonists such as secreted frizzled-related protein and dickkopf
protein. The first connection between BC and Wnt/β-catenin pathway was built based on
the discovery of Int-1, later known as Wnt1 (Nusse et al., 1984), and evidence showed that
the activation of int-1 gene transcription is associated with mammary gland hyperplasia
and following breast tumorigenesis (Tsukamoto et al., 1988). Subsequently research also
suggested that similar with the effects of Wnt1 on breast tumorigenesis, Wnt3 and Wnt10b
are able to induce breast tumor development (Roelink et al., 1990; Lane et al., 1997). In
addition, stabilized β-catenin has been demonstrated as the major characteristic
contributing to tumorigenic Wnt signaling (Incassati et al., 2010); moreover, the activation
of β-catenin signaling is responsible for increased invasion and metastasis capacity for
breast tumor progression via enhanced EMT (Klauzinska et al., 2012). Despite the
deregulated Wnt/β-catenin signaling and nucleus β-catenin accumulation is widely
involved in BC development, the somatic mutations related to Wnt/β-catenin signaling,
such as APC , CTNNB1 and Axin, in BC is rare (Yu et al., 2016); whereas, the
overexpression of Wnt corresponding receptors and epigenetic silencing of Wnt
antagonists play roles in the elevated activation of Wnt pathways (Zhan et al., 2017).

2.4.2 Inflammation Associated Tumorigenesis in Wnt-Signaling Pathway
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Although the chronic inflammation status is responsible for a tumor-favorable
microenvironment, it possesses synergistic effects with other tumorigenic pathways as well;
for example, Wnt/β-catenin signaling as one of the classical collaborative pathways is
under extensively research. Since obesity play a role in breast tumorigenesis, Wntsignaling is evidenced to involve in tumor progression promoted by diet-induced obesity
in C57BL/6 mice model implanted with MMTV-Wnt1 cells from transgenic mice; however,
in contrast to obese mice, lean mice showed a reduced tumor growth (Nunez et al., 2008).
To establish the causality between obesity and breast tumor, Zheng et al. (2011) found that
leptin is essential for MMTV-Wnt1 tumor growth in transplanted mice and also involves in
the development of cancer stem cells; whereas, Wang et al. (2006) indicated that contrary
to the pro-tumor effects of leptin in Wnt-signaling, adiponectin acts as an anti-tumor factor
for BC cell line MDA-MB-231 by decreasing phosphorylation of Akt and GSK-3β, leading
to decreased accumulation of β-catenin in cytoplasm and nucleus and downregulation of
cyclin D1 (CCND1) expression. In the context of obesity-related chronic inflammation,
leptin and adiponectin act as pro- and anti-inflammatory mediators, respectively; hence
their balance in mammary tissue profoundly modulates the inflammation and tumor
progression, on the other hand, both leptin and adiponectin are the intermediaries between
chronic inflammation and tumorigenic Wnt-signaling pathway.
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In the process of inflammation-related tumorigenesis, the crosstalk between tumor cells
and stromal cells as well as the secreted molecules in the a TME greatly promotes tumor
progression, and among the interactions, Wnt-signaling also plays a role. TAM
accumulation in BC as the major link between inflammation and cancer progression is
associated with BC progression and poor patient outcomes (Obeid et al., 2013). Evidence
has suggested that Wnt-signaling is positively incorporated in the crosstalk between tumor
cells and macrophages as well as cell derived inflammatory cytokines: Kaler et al. (2009a,b)
and Oguma et al. (2008) demonstrated that macrophage-derived IL-1β and TNF-α are able
to induce the phosphorylation of GSK-3β through NF-κB-dependent and -indepentdnet
pathway, leading to elevated tumorigenic β-catenin signaling in colorectal and gastric
cancers, respectively; Liu et al. (2012) proposed that the elevated TNF-α expression from
diet-induced obesity in C57BL/6 mice is correlated to the increased phosphorylation of
GSK-3β and β-catenin stabilization; our previous study on obesity-related breast
tumorigenesis also found that the TNF-α recombinant protein is capable of increasing the
expression of active β-catenin, whereas the anti-TNF-α antibody could attenuate β-catenin
accumulation (Roubert et al., 2017); TGF-β (Wu et al., 2017) and CXCL12 (Shan et al.,
2015) are shown to be stimulators for active Wnt/β-catenin signaling, leading to enhanced
invasion and metastasis of BC via the upregulation of EMT.
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In addition to the involvement of canonical pathway in inflammation-associated
tumorigenesis, non-canonical pathway also directly or indirectly contributes to tumor
progression. Proinflammatory cytokines such as IFN-γ (Newman et al., 2012) and TNF-α
(Shao et al., 2016) or lipopolysaccharide (LPS) (Newman et al., 2012; Shao et al., 2016)
are able to stimulate the expression of Wnt5a in macrophages, of which’s signaling is
generally participating in non-canonical pathways such as CaMKII, PKC and JNK (Shao
et al., 2016). Pukrop et al. (2006) showed that in a coculture cell model, the increased
secretion of Wnt5a by macrophage could stimulate the expression of Wnt targeted gene
MMP-7 and its regulated TNF-α secretion, leading to upregulation of MMP-2,3,9
expression within macrophages by autocrine mechanism; moreover, Wnt5a would go
through paracrine mechanism to stimulate the activation of AP-1/c-Jun signaling in MCF7. Taken together, Wnt5a possesses the ability to promote the invasive capacity of BC cells.
Besides, macrophage-derived Wnt5a is evidenced to be endowed with proangiogenic
effects by promoting the maturation of proangiogenic macrophages and the proliferation
and migration of endothelial cells, and enhancing the production of pro-inflammatory
cytokines as well as pro-angiogenic factors in macrophages by autocrine and paracrine
mechanisms (Newman et al., 2012). Other pro-tumor effects of non-canonical pathway
include the induction of proinflammatory mediators mediated by the activation of CaMKII,
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PKC, NF-κB, and MAPK signaling, and induced insulin resistance (Shao et al., 2016).

As the evidence outline in the previous session, progressive chronic inflammation is
responsible for the elevated estrogen concentration in both local and systemic levels. It is
noteworthy that estrogen could influence Wnt-signaling pathway. Several studies have
reported that beta-estradiol treated MCF-7 would upregulate the expression of frizzled-10
(Saitoh et al., 2002), WNT2 (Katoh, 2001) and WNT5B (Saitoh et al., 2002), resulting in
the raised activation of Wnt/β-catenin signaling. In summary, Wnt-signaling pathway is not
only involved in tumorigenesis triggered by mutations or epigenetic alteration in tumor
cells, but the chronic inflammation caused upregulation of proinflammatory mediators and
estrogen level as well as the crosstalk between tumor cells and stromal cells in the whole
TME profoundly influence the activation of this pathway.

2.5 The Prevention of Breast Cancer: With A Focus on Mushrooms

Phytochemicals and bioactive compounds in plant-based foods are widely accepted as plant
nutrients with some specific biological functions that are beneficial to human health and
possess positive effects on various human disease. Among these foods, mushrooms are
considered as flavorful delicacies in a part of the human diet for many years across the
global. Mushrooms, technically, are classified as fungi and generally regarded as
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vegetables because of their nutritious properties. Around the world, more than 12,000
species of mushrooms exist in nature, however, only ~20-30 species are widely accepted
as cultivated edible mushrooms (Feeney et al., 2014; Valverde et al., 2015; Rathore et al.,
2017).

2.5.1 Market Trends of Mushrooms

In many cultures, the extensively use of mushrooms in cuisine has been an indispensable
part for centuries, even some of the Asian cultures believe them to have medicinal value
and apply them into traditional medicine to treat various disease (Khan et al., 2013). The
global production of mushrooms had dramatically grown from less than 1 million metric
tons in 1970 to 10.7 million metric tons in 2016 (FAOSTAT, 2018). In 2016, China, Italy,
United States of America, Netherlands and Poland were the top 5 countries for the
production of mushrooms and truffles, and they were reported to produce 72%, 6%, 4%,
3% and 2% of global mushrooms and truffles (FAOSTAT, 2018). The production and sales
of mushrooms in the USA is gradually increased from $0.8 to $1.2 billion during 19972017 (National Agricultural Statistics Service, USDA, 2018). The cash receipt for
mushrooms in the USA in 2016 is ranked 28th among all agricultural commodities, but
ranked 4th among vegetables (Economic Research Service, USDA, 2018). However, the
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mushroom production in the USA is predominantly supplied for domestic utilization, and
only less than 5% of mushroom supplies exported annually (Feeney et al., 2014). In
addition to the economic value, the cultivation of mushrooms also is environmental
friendly that the required land and water for the growth of cultivated mushrooms are
relatively less than other crops, moreover, spent mushroom substrate is an excellent source
as a soil amendment for crops or a garden (Feeney et al., 2014).

2.5.2 Nutritional Value of Mushrooms

Long honored as a superfood with high nutritional and functional value, mushrooms
provide high protein, high fiber, abundant sources of vitamins and minerals, but low fat
contents (Mattila et al., 2001; Wang et al., 2014). Carbohydrates found in mushrooms
mainly consist of mannitol and high proportion of non-digestible polysaccharides such as
β-glucans, chitin and mannans (Cheung, 2010). One of the significant differences between
mushrooms and most vegetables is their protein content, mushrooms contain higher
proportion of protein, of which’s nutritional quality is higher than that of other plant protein,
providing all the essential amino acids for human, even some of the species possessing the
comparable protein composition with that of hen’s egg (Wang et al., 2014). In addition, the
low amount of fat is composed of high proportion of unsaturated fatty acids, such as linoleic
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and oleic acid (Valverde et al., 2015). Mushrooms are also a good source of several
vitamins and minerals, including riboflavin (vitamin B2), niacin, folate, vitamin B12, D, E,
potassium, phosphorus, magnesium, zinc, copper and selenium (Cheung, 2010; Feeney et
al., 2014; Valverde et al., 2015). Beyond the nutritional value of mushrooms, they are able
to synthesize a bunch of biologically active components, including some bioactive
carbohydrates, proteins, lipids and secondary metabolites (Valverde et al., 2015), that
possess diverse positive effects against various human diseases. Nowadays, mushrooms
are recognized as a functional food and are getting worldwide attention on their
nutraceutical attributes and pharmacological characteristics.

Figure 5. Nutritional value of mushrooms
2.5.3 The Health Beneficial Properties of Mushrooms
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The health benefits of mushrooms for human, including improved cognition, autoimmune
disease, chronic disease such as asthma, obesity, diabetes, cardiovascular diseases and
cancers, are mainly discovered on the basis of previous in vitro experiments and in vivo
animal trials, and these health-promoting effects are evidenced mostly attributing to the
biological activities of mushrooms on the aspects of immunomodulation, interaction with
gut microbiota, and anti-cancer effects (Roupas et al., 2012).

Immunomodulation. One of the most well-known health-promoting effects of
mushrooms is their anti-inflammatory and immunomodulatory including both
immunosuppressive and immunostimulatory properties. These properties are attributed to
the wide variety of bioactive compounds in mushrooms such as bioactive saccharides,
proteins, fatty acids, vitamins and minerals, secondary metabolites including phenolic
compounds, indole compounds and terpenoids (Muszyńska et al., 2018).

Macronutrients: β-glucans are the most abound polysaccharides exist in mushrooms, and
researches on β-glucans indicate they possess anti-inflammatory and immunostimulatory
effects by inhibiting NF-κB, COX-2 and inducible nitric oxide synthase (iNOS) signaling
in RAW 264.7 macrophages (Ma et al., 2013) and enhancing the proliferation and
stimulation of immune cells such as macrophages and NK cells (Akramiene et al., 2007),
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respectively. Proteins such as mushroom lectins and fungal immunomodulatory proteins
are characterized as immunoregulatory factors directly targeting immune cells for
activating both innate and adaptive immunity (Wang et al., 1996; Sze et al., 2004; Xu et al.,
2011). Polyunsaturated fatty acids, especially α-linolenic acid (ALA), are generally
considered as anti-inflammatory factors. Indeed, study conducted by Grzywacz et al. (2016)
showed that high ALA content found in Imleria badia play a role in the inhibition of LPSinduced inflammatory responses in RAW 264.7 macrophages.

Micronutrients: antioxidative vitamins such as ascorbic acid, tocopherols as well as
carotenoids are important not only for their role in free radical scavenging, but also in
preventing inflammatory cytokines production (Grimble, 1997). Ergosterol (vitamin D
precursor) and ergocalciferol (vitamin D2) found in mushrooms are important food sources
of vitamin D, which possesses a board beneficial effects for human. Babu et al. (2014)
demonstrated that 10 weeks feeding of ultraviolet-B light (UVB)-exposed white button
(WB) mushrooms powder for Sprague-Dawley rats significantly increased the plasma total
25-hydroxyvitamin D levels, promoted innate immunity as well as improved antiinflammatory effects in LPS-challenged rats compared to rats feeding without VitD
enrichment (UVB exposure). Another experiment conducted by Drori et al. (2016)
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demonstrated that in an immune-mediated hepatitis mice model, after the feeding of UVBexposed Lentinula edodes (shiitake mushroom) powder for C57B1/6 mice treated with
concanavalin A, the liver damage and plasma IFN-γ was alleviated compared to
nonenriched mushroom group. In addition, the authors also pointed out that vitamin D may
have synergistic effects with other bioactive compounds in mushroom on antiinflammatory activities.

Other bioactive compounds: phenolic compounds in mushrooms exerting antiinflammatory effects is partially attributed to their role as antioxidants. Caffeic acid, for
example, has been shown to attenuate vascular inflammation by inhibiting NF-κB signaling
and the expression of cell adhesion molecules, chemoattractants such as MCP-1 and IL-8
in the TNF-α-induced human umbilical vein endothelial cells (Moon et al., 2009). Indole
compounds such as melatonin and serotonin possess immunoregulatory effects including
immunostimulation and/or anti-inflammation by targeting various immune cells (CarrilloVico et al., 2013; Herr et al., 2017). Triterpenes derived from Ganoderma lucidum are
endowed with immunomodulatory and anti-inflammatory effects by inhibiting NF-κB
signal transduction or other transduction pathways such as AP-1/ nuclear factor of activated
T-cells (NF-AT) and STAT3 signaling (Ríos, 2010; Muszyńska et al., 2018).
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Gut microbiota. The microbiota inhabiting in human gastrointestinal (GI) tract is
comprised of more than 1014 microorganisms (10 times more than the number of human
cells), with over 1000 species of known bacteria encompassing more than 3 million genes
(150 times more than human genome) (Jayachandran et al., 2017). The complexity makes
gut microbiota a dynamic ecosystem that is profoundly influenced by multiple factors
through the lifetime including genotype, the mode of delivery at birth and infant feeding,
diet, lifestyle, stress and environmental exposures. A healthy and balanced gut microbiota
could contribute many benefits to the host such as strengthening gut barrier (Natividad et
al., 2013), protecting against pathogens (Bäumler et al., 2016), xenobiotic metabolism
(Claus et al., 2016), regulating host energy and immune homeostasis (Wu et al., 2012;
Rosenbaum et al., 2015); whereas, a disrupted gut microbiota would lead to various
diseases.

One of the major role of mushrooms in improving health is by providing prebiotics such
as non-digestible oligosaccharides and polysaccharides to ameliorate and maintain the
host’s gut microbiota. Recent study has shown that C57BL/6 mice feeding with 1% WB
mushrooms (1 g/100 g diet) for 2-4 weeks displayed an increased diversity of gut
microflora by increasing the Bacteroidetes phyla and decreasing the Firmicutes phyla
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including pathogenic bacteria Clostridia, compared to mice feeding with control diet
(Varshney et al., 2013). Research also points out that the ratio between Firmicutes and
Bacteroidetes is intimately associated with obesity. Chang et al. (2015) demonstrated that
the consumption of the water extract of Ganoderma lucidum mycelium in C57BL/6 mice
feeding with high-fat diet (HFD) for 2 months showed a significant reduced weight gain
and fat accumulation by reversing HFD-induced gut dysbiosis characterized by an
increased Firmicutes to Bacteroidetes ratio.

The fact that the growth of specific gut bacteria is favored by distinct polysaccharides and
the intervention of certain polysaccharides or oligosaccharides could alter the composition
of human gut microbiota to a healthier and balanced condition (Koropatkin et al., 2012)
gives rise to a prosperous research on the field of gut microbiota and prebiotics.
Mushrooms as a potential source of prebiotic polysaccharides and oligosaccharides are
now under an extensively exploration. For example, polysaccharides derived from
Lentinula edodes, Phellinus linteus, Trametes versicolor and Hericium erinaceus are
proved to render an alteration of gut microflora that could promote host’s health
(Jayachandran et al., 2017).

Anti-cancer effects. The anti-cancer effects of mushrooms are largely due to the above-
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mentioned two characteristics that are responsible for the regulation of both innate and
adaptive immune systems, leading to effective anti-cancer immunosurveillance. On the
other hand, various bioactive compounds found in mushrooms also possess diverse antitumor activities such as pro-apoptosis, anti-proliferation, anti-invasion, anti-metastasis,
and anti-angiogenesis, which are dependent on the suppression of several tumorigenesis
signaling such as phosphoinositide 3-kinase (PI3K)/AKT, Wnt/β-Catenin, and NF-κB
signaling pathways (Joseph et al., 2017).

2.5.4 Mushrooms and Breast Cancer Prevention

The benefits of mushrooms on the prevention of BC are generally demonstrated by in vitro
or in vivo studies, as well as a limited number of epidemiological studies. Clinical
intervention trails related to oral administrations of mushrooms conducted in humans are
rare. Epidemiological studies suggested that per 1 g/day increased mushroom intake is
associated with 0.97 BC relative risk, and this correlation exists in both pre- and postmenopausal women (Li et al., 2014). In addition, adjuvant treatments of BC with dietary
supplementation with mushrooms or mushroom extracts have shown to improve the quality
of life and survival rates of patients (Novaes et al., 2011; Eliza et al., 2012).

Myriad pre-clinical researches on biologically active substances derived from various
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mushrooms have revealed that the anti-cancer activities of mushrooms are directly
attributed to the diverse bioactive components found in mushrooms. The major bioactive
components in mushrooms are polysaccharides, and their anti-tumor activities are
extensively addressed. For example, Lu et al. (2011) revealed that polysaccharide Krestin
extracted from Trametes versicolor are capable of inducing dendritic cell (DC)-mediated
TH1 immune response and stimulating cytotoxic T cells and NK cells against BC growth
in C57BL/6 mice. Jeong et al. (2012) indicated that polysaccharides extracted from WB
mushrooms are able to activate J774A.1 macrophages toward tumoricidal ones and possess
cytotoxicity against MCF-7 BC cell line. A study conducted by Shi et al. (2013) showed
that polysaccharides isolated from Pleurotus abalonus could induce ROS-mediated cell
apoptosis in MCF-7 cells. In addition, Alonso et al. (2013) demonstrated that
polysaccharide complexes derived from Maitake mushroom are responsible for the antitumor effects, such as pro-apoptosis, anti-proliferation, anti-metastasis and improving drug
sensitivity, in MCF-7 cells.

Other bioactive compounds of mushrooms that possess anti-BC effects include lectins
(Savanur et al., 2014), terpenoids such as ganoderic acids (Jiang et al., 2008) and
ganodermanontriol (Jiang et al., 2011), and secondary metabolite panepoxydone (Arora et
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al., 2014). The anti-BC functions of these bioactive compounds mainly relates to the
induction of apoptosis and suppression of proliferation and invasion, which are preventive
functions generally for almost all types of cancer. Specifically for BC, several previous
studies pointed out that phytochemicals extracted from WB mushrooms would block ER+
BC proliferation in in vitro and in vivo by suppressing aromatase activity (Grube et al.,
2001; Chen et al., 2006).

2.5.5 Antrodia Camphorata

AC is a rare medicinal fungus parasitic on the Cinnamomum kanehirae Hayata (bull
camphor tree), which only grows in Taiwan. AC, also known as “niu-chang-chih” in
Chinese name, is commonly used in Taiwanese traditional medicine for alcohol
intoxication, diarrhea, abdominal pain, hypertension, fatigue, viral infection and liver
disease (Geethangili et al., 2011).

As other mushrooms, AC also possesses anti-inflammatory and immunomodulatory effects.
In LPS-stimulated macrophages, AC extracts were reported to suppress the enhanced
production of nitric oxide, TNF-α, IL-1β, IL-12, PGE2 as well as iNOS and COX-2 protein
expression via inhibiting NF-κB signaling pathway (Hseu et al., 2005; Rao et al., 2007)
and STAT3 signaling (Lin et al., 2017b). AC extracts and bioactive compounds found in
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AC such as zhankuic acids and antcin K also could inhibit the production of inflammatory
mediator ROS in activated neutrophils or mononuclear cells (Shen et al., 2004a; b). In
addition, Kuo et al. (2008) demonstrated that AC extracts could enhance innate immune
response by upregulation TNF-α and IL-6 expression and polymorphonuclear neutrophils
(PMN)- and monocytes -mediated phagocytosis in diluted peripheral blood culture.
Although according to previous studies AC has been proven to have effective
immunomodulatory properties, its role in inflammatory tumorigenesis within a TME
remains unclear.

A series in vitro and in vivo experiments for identifying the anti-BC effects of fermented
culture broth of AC have suggested that it could induce tumor-specific ROS-mediated
apoptosis and cell cycle arrest against hormone receptor-positive and -negative and
HER2/neu-overexpressing BC (Yang et al., 2006; Hseu et al., 2007; Hseu et al., 2008; Lee
et al., 2012). In addition to the selective cytotoxic effects, it is able to suppress COX-2 and
HER2/neu expression and inhibit PI3K/AKT and β-catenin signaling, of which’s
upregulations are involved in cancer invasion and metastasis (Hseu et al., 2007; Lee et al.,
2012).

Recently, researchers have isolated a new group of bioactive compounds, ubiquinon
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derivatives, including AQ and 4AAQB, from the AC mushrooms. These compounds are
shown to exhibit inhibitory effects against BC growth and metastases (Lee et al., 2015) as
well as anti-inflammatory effects (Chang et al., 2018). Their anti-tumor effects also have
been reported in hepatomas (Lin et al., 2011), brain cancer (Thiyagarajan et al., 2015),
pancreatic cancer (Yu et al., 2012), lung cancer (Kumar et al., 2011), colorectal cancer
(Chang et al., 2015; Lin et al., 2017a) and ovarian cancer (Liu et al., 2017). However, due
to limited studies, the immunomodulatory efficacy of these compounds is still not clear,
not to mention their influence on the interaction between inflammation and BC progression.

2.6 Conclusions and Perspectives

In the light of the concept of TME, the links between inflammation and BC progression
are well-established. Within a TME, inflammatory mediators such as cytokines,
chemokines and PGs play critical roles in promoting breast tumor growth and metastases
by suppressing anti-tumor immunity and triggering multiple oncogenic signaling pathways,
including NF-κB, STAT3 and Wnt/β-catenin signaling. On the other hand, these mediators
could also stimulate the activation of aromatase, leading to enhanced estrogen production
and contributing to BC promotion and repression of tumor immunosurveillance. AC, as a
traditional Chinese medicine in Taiwan, has been of interest in CAM research in recent
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decades. Although there is a quite amount of evidence from pre-clinical experiments that
suggests meaningful association between AC and cancer risk, it remains unclear which
food components actually account for protection against cancer, and which cellular
processes are critically involved. Recently, new bioactive components, AQ and 4-AAQB
were isolated from AC, and have been regarded as promising bioactive compounds in
treating various cancer, including BC. A greater understanding of specific molecular targets
for AQ and 4-AAQB is fundamental to establish them as complementary and alternative
strategies for reducing cancer in humans.
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CHAPTER 3
PURPOSE OF THE STUDY

Numerous studies have indicated that chronic inflammation acts as a risk factor as well as
tumor-promoting factor for BC development. Inflammatory mediators such as cytokines,
chemokines and PGs produced by various cells including cancer cells are proposed to be
the key regulators in BC progression through an autocrine/paracrine mechanism. Multiple
studies also indicated that these mediators could further interfere with estrogen production,
oncogene expression, and tumor immunosurveillance within a TME, leading to advanced
BC. Recently, two novel bioactive components, AQ and 4-AAQB have been isolated from
AC mushroom and are recognized as potential anti-cancer and anti-inflammatory natural
compounds; however, their effect on immunomodulation in BC is still unknown. We
therefore propose to characterize the effects of AC and 4-AAQB on the expression of BCrelated inflammatory mediators and examine their effects on the aromatase activity as well
as Wnt-signaling responses with or without the stimulation of TNF-α, one of the most
critical inflammatory cytokines in the breast TME.

Specific Aim #1: To characterize the influences of AQ and 4-AAQB on the production
of inflammatory mediators in the MCF-7 BC cell line with or without TNF-α
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stimulation. Our working hypothesis is that TNF-α stimulation on MCF-7 BC cells would
deteriorate the gene expression profile of inflammatory mediators and treatment with AQ
and 4-AAQB to MCF-7 cells could improve the gene expression profile of inflammatory
mediators before and after TNF-α stimulation.

Specific Aim #2: To examine the impact of AQ and 4-AAQB on the expression of
aromatase in the MCF-7 BC cell line. Our working hypothesis is that TNF-α stimulation
on MCF-7 BC cells would upregulate the gene expression of aromatase and treatment with
AQ and 4-AAQB to MCF-7 cells could suppress the gene expression of aromatase before
and after TNF-α stimulation.

Specific Aim #3: To examine the influences of AQ and 4-AAQB on immunecheckpoint CD47 and tumorigenic Wnt-signaling downstream genes. Our working
hypothesis is that TNF-α stimulation on MCF-7 BC cells would upregulate the gene
expression of immune-checkpoint CD47 and Wnt-signaling responses and treatment with
AQ and 4-AAQB to MCF-7 cells could inhibit the gene expression of CD47 and Wntsignaling responses.
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CHAPTER 4
MATERIALS AND METHODS

Our experiment aimed to identify the role of AQ and 4-AAQB in the modulation of
inflammatory mediators as well as their associated gene expression in MCF-7 BC cells
with or without TNF-α stimulation. The appropriate doses for AQ/4-AAQB and TNF-α
treatment was first evaluated by using MTT assays. The gene expression of inflammatory
mediators, aromatase and Wnt-signaling downstream genes was measured in the treated
MCF-7 cells by using quantitative real-time PCR to determine the effects of TNF-α
stimulation and AQ/4-AAQB treatment with or without TNF-α stimulation in MCF-7 cells.

4.1 Experimental Design

See Table 1. in the Appendix

4.2 Reagents and Chemicals

The compounds antroquinonol (AQ, > 99% purity) and 4-acetylantroquinonol B (4-AAQB,
> 99% purity) were obtained from New Bellus Enterprises Co., Ltd. (Tainan, Taiwan). AQ
and 4-AAQB were dissolved in dimethyl sulfoxide (DMSO, Santa Cruz Biotechnology
Inc., Dallas, TX) to make 25mM and 50mM stock solutions, respectively. The stock
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solutions were filter-sterilized and stored at -20°C in aliquots. Dulbecco's modified Eagle
medium (1X) (DMEM, Gibco™), heat-inactivated fetal bovine serum (FBS, Gibco™),
phosphate buffered saline (1X) (PBS, Gibco™), 0.25% trypsin-EDTA (1X) (Gibco™),
penicillin-streptomycin (10,000 U/mL) (Gibco™), TRIzol® reagent (Invitrogen™), highcapacity cDNA reverse transcription kit (Applied Biosystems™) and PowerUp™ SYBR™
green master mix (Applied Biosystems™) were purchased from Thermo Fisher Scientific
Co. (Waltham, MA). DEPC-treated water was purchased from Santa Cruz Biotechnology
(Dallas, TX). 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium Bromide (MTT,
Calbiochem®) was purchased from MilliporeSigma (Burlington, MA). MTT were
dissolved in PBS to make a 5 mg/ml stock solution. The MTT stock solution were filtersterilized and stored at -20°C in aliquots. Recombinant human TNF-α was purchased from
PeproTech Inc. (Rocky Hill, NJ). rhTNF-α was reconstituted in sterile double distilled
water containing 0.1% bovine serum albumin (BSA, Cell Signaling Technology Inc.,
Danvers, MA) to make a 100ng/μL stock solution and was stored at -20°C in aliquots.

4.3 Cell Lines and Cell Culture

Breast cancer cell line MCF-7 was obtained from American Type Culture Collection
(ATCC, Manassas, VA). MCF7 cells were maintained in DMEM supplemented with 10%
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FBS, 100 U/mL penicillin and 100 μg/mL streptomycin and 1 mM sodium pyruvate at
37 °C in a humidified incubator containing 5% CO2. Cells were sub-cultured at 80%
conflueny, and culture medium was replaced every 72 hours.

4.4 Cell Viability Assays

MCF-7 cells were seeded in 96-well plates with 2×104 cells per well and incubated for 48
hours. After cell growth reached 80% confluency, cells were subsequently starved in
DMEM containing 0.5% FBS overnight. After starvation, cells were either treated with
DMEM containing 0.5% FBS and AQ/4-AAQB (0~50 µM with DMSO<0.01%) or control
medium containing 0.5% FBS for 24 hours and 48 hours or treated with medium containing
0.5% FBS and rhTNF-α (0~10 ng/mL) or rhTNF-α (0~10 ng/mL) combining with AQ/4AAQB (0.4 µM with DMSO<0.01%) for 24 hours. Blanks were incubated with culture
medium without seeding cells. Cell viability was determined by incubation with MTT (0.5
mg/mL) for 1 hour. Formazan crystals were dissolved in DMSO, and the absorbance was
measured by a SpectraMax microplate reader (Molecular Devices, Sunnyvale, CA) at 570
nm wavelength. The average value obtained from blanks was subtracted from average
values obtained from treatment and control groups. Cell viability was expressed as a
percentage compared to control. Experiments were performed in sextuplicate.
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4.5 Quantitative Real Time PCR Analyses

RNA extract and cDNA preparation: MCF-7 cells were seeded in 6-well plates with 6×105
cells per well and incubated for 48 hours. After cell growth reached 80% confluency, cells
were subsequently starved in DMEM containing 0.5% FBS overnight. After starvation,
cells were either treated with DMEM containing 0.5% FBS and AQ/4-AAQB (0.4 µM with
DMSO<0.01%) or control medium containing 0.5% FBS for 24 hours or treated with
DMEM containing 0.5% FBS and rhTNF-α (0.2 ng/mL) or rhTNF-α (0.2 ng/mL)
combining with AQ/4-AAQB (0.4 µM with DMSO<0.01%) or control medium containing
0.5% FBS for 0.5, 1, 2, 3, 4 hours. Total RNAs from MCF-7 cells were extracted by using
TRIzol reagent (Invitrogen™) according to the manufacturer's instructions. cDNA was
synthesized from RNA samples by using high-capacity cDNA reverse transcription kit
(Applied Biosystems™).

Gene expression analysis: The expression of target genes was measured by ViiA™ 7 RealTime PCR System (Applied Biosystems®). Relative gene expression levels were
calculated by ΔΔCt method with GAPDH acting as the reference gene. Statistical analyses
were based on ΔCt. ΔCt is defined as Ct (target gene) – Ct (ref. gene), and ΔΔCt is defined as ΔCt
(treatment)

– ΔCt (control). The design of DNA primers for target genes (IL1β, IL6, IL10, IFNγ,
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TNF, TGFβ1, PTGS2, CCL2, CSF1, CYP19A1, CD47, CCND1, C-MYC, AXIN2 and
GAPDH) were available from PrimerBank (https://pga.mgh.harvard.edu/primerbank/). All
primers were ordered from Thermo Fisher Scientific (Invitrogen™ Custom DNA Oligos).
A list of the primers used can be found in Table 2. in the Appendix.

4.6 Statistical Analysis

All statistical analyses were performed in Excel and SAS. Statistical significances were
evaluated by unpaired t test, and time-dependent associations were assessed by CochranArmitage test for trend. P-value < 0.05 was considered to be statistically significant.
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CHAPTER 5
RESULTS

5.1 Cell Viability Assay of AQ and 4-AAQB Treatment in MCF-7 Cells

In order to determine the appropriate treatment dosage for AQ and 4-AAQB, we treated
MCF-7 cells with AQ and 4-AAQB. After 48 hours of treatment with either of these
compounds at different concentrations (0-1.6 μM), the cell viability was measured by MTT
assay. The results showed that the reduction of cell number was in parallel with the elevated
concentration of AQ and 4-AAQB compared to untreated control (Figure 6A). Specifically,
the cell growth inhibition in 4-AAQB treatment against MCF-7 cells was greater than in
AQ treatment. Both treatment showed a modest cytotoxic response (~24%) toward MCF7 cells while the concentration below 0.4 μM; therefore, we decided to use 0.4 μM as our
treatment dosage for AQ and 4-AAQB in the following experiments.

5.2 Cell Viability Assay of TNF-α Treatment in MCF-7 Cells

Appropriate treatment concentration for TNF-α is also determined by MTT assay. MCF-7
cells were treated with TNF-α at different concentrations (0-10 ng/mL) or treated with
TNF-α combined with 0.4 μM AQ or 4-AAQB. After 24 hours of treatment, results showed
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that TNF-α exhibited a growth inhibitory effect on MCF-7 cells; whereas, the combination
treatment with AQ or 4-AAQB partially abrogated the inhibitory effects of TNF-α (Figure
6B). TNF-α showed a moderate cytotoxic response (~40%) at 0.2 ng/mL, while the
combination treatments exhibited a less effective cytotoxicity (~20%) with 0.2 ng/mL
TNF-α. Hence, we decided to use 0.2 ng/mL TNF-α as our treatment dosage for the
following experiments.

Figure 6. AQ, 4-AAQB and TNF-α reduce cell viability of MCF-7 cells. (A) Growth
inhibitory effects of AQ and 4-AAQB against MCF-7 cells after 48 h treatment. (B) Growth
inhibitory effects of TNF-α against MCF-7 cells after 24 h treatment. Cell viability is
measured by MTT assay and is expressed as the percentage viability relative to the
untreated control group. All experiments were performed in sixplicate and data are
presented as mean ± SEM. *P < 0.05, as compared to TNF-α treatment.
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5.3 AQ and 4-AAQB Alter the Inflammatory Mediators Profile of MCF-7 Cells

To evaluate the effects of AQ and 4-AAQB on the modulation of inflammatory status in
MCF-7 cells, gene expression levels of 9 inflammatory mediators (IL6, IL10, IL1β, IFNγ,
TNF, TGFβ1, PTGS2, CCL2 and CSF1) were measured using quantitative real-time PCR
analyses (Applied Biosystems®). Unpaired t tests were calculated to evaluate the
differences between control group and treatment group.

The heatmap of AQ treatment showed that the expression levels of PTGS2, TNF, IL10,
CCL2, IL6 and TGFβ1 is lower in AQ treatment group than in control group (Figure 7A).
Significantly inhibition by AQ treatment compared to control were found in the expression
levels of IL10 (44.0%) and PTGS2 (42.2%) (p-values were 0.026 and 0.040, respectively;
Figure 7B). The expression of TNF, TGFβ1, CCL2 and IL6 in AQ treatment group exhibited
a decreased trend compared to control (35.7%, 19.3%, 32.7%, respectively; Figure 7B).
Similar to the effect of AQ treatment, 4-AAQB lower down the expression levels of TNF,
PTGS2, IL10, IL6, IL1β, CCL2 and TGFβ1 as well but with a stronger suppressive effect
(Figure 8A). Compared to untreated control, the expression of TNF, PTGS2 and IL10 were
significantly inhibited in 4-AAQB treatment by 46.2%, 48.4%, 53.4%, respectively (pvalues were 0.002, 0.013 and 0.017, respectively; Figure 8B). The expression of IL6 and
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IL1β exhibited a decreased trend in 4-AAQB treatment compared to control (50.3% and
21.6%, respectively; Figure 8B). However, the expression level of CSF1 was significantly
increased 19.0% after 4-AAQB treatment, which was not a case in AQ treatment group
(Figure 8B).
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Figure 7. Heatmap (A) and relative gene expression level (B) of targeted inflammatory
mediators in MCF-7 cells with or without 24 h AQ treatment. Relative expression was
calculated by △△Ct method, and all statistical analyses were based on △Ct values.
Unpaired t test was applied to identify the difference between control and treatment groups.
All experiments were performed in tetraplicate and data are presented as mean ± SEM.
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Figure 8. Heatmap (A) and relative gene expression level (B) of targeted inflammatory
mediators in MCF-7 cells with or without 24 h 4-AAQB treatment. Relative expression
was calculated by △△Ct method, and all statistical analyses were based on △Ct values.
Unpaired t test was applied to identify the difference between control and treatment groups.
All experiments were performed in tetraplicate and data are presented as mean ± SEM.
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5.4 AQ and 4-AAQB Suppress IL6 Upregulation but Strengthen IFNγ Upregulation
Induced by TNF-α Stimulation

TNF-α as one of the most common cytokines majorly secreted by macrophages in a breast
TME was reported to be a strong inducer for the activation of inflammatory response
pathway, leading to the upregulation of a variety of inflammatory mediators. To evaluate
the inhibitory effect of AQ and 4-AAQB on the inflammatory status induced by TNF-α in
MCF-7 cells, gene expression levels of IL6, IL10, IFNγ, PTGS2 and CCL2 were measured.
Cochran-Armitage test for trend were performed to analyze the relationship between time
and expression levels; unpaired t tests were calculated to evaluate the differences between
control group and treatment group.

By adding rhTNF-α to stimulate MCF-7 cells, gene expression of inflammatory mediators,
including IL10, PTGS2, IL6, IFNγ, and CCL2, showed a time-dependent increase (p for
trend values were 0.005, < 0.0001, < 0.001, 0.035 and < 0.0001, respectively; Figure
9A~E). However, 4 hours after AQ/4-AAQB and TNF-α cotreatment, only the induced
upregulation of IL6 was significantly suppressed up to 51.4% and 35.9% by AQ and 4AAQB, respectively (p-values were 0.0002 and 0.009, respectively; Figure 9F). In contrast,
the expression level of IFNγ was further upregulated 182.5% and 113.6% while cotreating
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with 4-AAQB rather than with AQ for 3 and 4 hours, respectively (p-values for 3 h was
0.033, for 4 h was 0.034; Figure 9G). Moreover, AQ showed a stronger inhibitory effect
(~29.4%) on the upregulation of CCL2 induced by TNF-α but did not achieve statistical
significance (p-value for 3 h was 0.062; Figure 9H).
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Figure 9. Gene expression levels of targeted inflammatory mediators in MCF-7 cells after
TNF-α stimulation (A~E) Gene expression levels of IL6 (F), IFNγ (G) and CCL2 (H) after
TNF-α and AQ/4-AAQB cotreatment. Relative expression was calculated by △△Ct method,
and all statistical analyses were based on △Ct values. Cochran-Armitage test for trend and
unpaired t test was applied to identify the time-dependent manner of TNF-α stimulation
and difference among control and treatment groups, respectively. All experiments were
performed in triplicate and data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P
< 0.001.
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5.5 AQ and 4-AAQB Inhibit the Expression of Aromatase in MCF-7 Cells

Aim to evaluate the potential effect of AQ and 4-AAQB on the production of estrogen in
breast cancer, we measured the gene expression level of aromatase (CYP19A1) in MCF-7
cells before and after treatment. Aromatase expression was significantly suppressed by up
to 50% in both AQ and 4-AAQB treatment groups (p-values were 0.044 and 0.036,
respectively; Figure 10A). Since TNF-α in a TME is positively correlated to the aromatase
activity (Zhao et al., 1996), our data also showed that the expression of aromatase in MCF7 cells was time-dependently increased after 0.2 ng/mL TNF-α induction (p for trend value
was < 0.001; Figure 10B). However, after 3 and 4 hours cotreatment with 0.4 μM 4AAQB, the elevated expression of aromatase induced by TNF-α was significantly inhibited
by 37.6% and 47.9%, respectively (p-values were 0.040 in 3 h treatment and 0.031 in 4 h
treatment; Figure 10C); moreover, after 4 hours cotreatment, the inhibitory effect against
TNF-α induction in 4-AAQB group was even significantly stronger than in AQ group (pvalue was 0.044; Figure 10C), which also was a similar case exhibited while only AQ and
4-AAQB treatment in MCF-7 cells (mean expression level was 0.525 and 0.471,
respectively; Figure 10A).
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Figure 10. Gene expression levels of aromatase (CYP19A1) in MCF-7 cells after either
AQ/4-AAQB treatment (A) or TNF-α treatment (B) or TNF-α and AQ/4-AAQB
cotreatment (C). Relative expression was calculated by △△Ct method, and all statistical
analyses were based on △Ct values. Cochran-Armitage test for trend and unpaired t test
was applied to identify the time-dependent manner of TNF-α stimulation and difference
among control and treatment groups, respectively. All experiments were performed in
triplicate and data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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5.6 Effects of AQ and 4-AAQB on the Expression of CD47 and Wnt Targeted Genes
in MCF-7 Cells

To investigate the influence of AQ and 4-AAQB treatment on the expression of immune
checkpoint and Wnt signaling response in MCF-7 cells, the expression levels of CD47 and
Wnt targeted genes C-MYC, CCND1 and AXIN2 were measured before and after treatment.
The gene expression level of CD47 was significantly suppressed by 17.3% and 27.4% after
AQ and 4-AAQB treatment, respectively (p-values were 0.044 and 0.007, respectively;
Figure 11A); whereas, CD47 expression was not influenced by TNF-α stimulation, either
the inhibitory effect of AQ and 4-AAQB on CD47 expression was abrogated after TNF-α
stimulation (data not shown). The expression level of C-MYC was suppressed by 28.6%
and 40.3% after AQ and 4-AAQB treatment, however, data analysis only showed a
statistical significant in 4-AAQB treatment group compared to control (p-value was 0.001;
Figure 11A). CCND1 and AXIN2 expression showed no difference after AQ and 4-AAQB
treatment relative to control group (data not shown). On the contrary to the upregulation of
expression of inflammatory mediators and aromatase induced by TNF-α stimulation, CMYC expression levels was time-dependently suppressed by TNF-α (p for trend value was
<0.001; Figure 11B), and CCND1 expression also showed a decreased trend paralleled to
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treatment time period (p for trend value was 0.067; Figure 11B). After 3 and 4 hours of
TNF-α and AQ/4-AAQB cotreatment, only C-MYC expression among the three Wnt
targeted genes was further suppressed by 32.9% and 24%, respectively, after combination
treatment of TNF-α and AQ (p-values were 0.006 and 0.008, respectively; Figure 11C),
while the expression levels after combination treatment of TNF-α and 4-AAQB for 3 and
4 hours showed no difference compared to TNF-α treatment group (Figure 11C).
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Figure 11. Gene expression levels of CD47 and Wnt targeted genes in MCF-7 cells after
either AQ/4-AAQB treatment (A) or TNF-α treatment (B) or TNF-α and AQ/4-AAQB
cotreatment (C). Relative expression was calculated by △△Ct method, and all statistical
analyses were based on △Ct values. Cochran-Armitage test for trend and unpaired t test
was applied to identify the time-dependent manner of TNF-α stimulation and difference
among control and treatment groups, respectively. All experiments were performed in
triplicate and data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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CHAPTER 6
DISCUSSION

Breast cancer as one of the leading diseases among women globally has long been focused
on in the biomedical area. However, in most of the cases, surgery still remains the primary
treatment nowadays. Although several medical treatments including hormone therapy,
chemotherapy, targeted therapy and radiotherapy are used clinically against breast cancers,
any one of these therapies solely is not enough to treat breast cancer effectively; hence a
combination treatment strategy is recommended. Since the important role of wellfunctioned immune system in anti-tumor strategy is widely studied over the past decades,
cancer immunotherapy becomes a promising adjuvant treatment for cancer therapy that
could potentially boost human immune system against cancers, including breast cancers.

As previous reviewed, a TME is under a chronic inflammatory status, and the relationship
between inflammation and cancer can be involved in two pathways, intrinsic and extrinsic
pathway (Mantovani et al., 2008). Genetic mutations of cancer-related oncogenes, tumor
suppressor genes and inflammation-related genes caused by randomly occurring or
environmental factors through the intrinsic pathways are capable of activating related
transcription factors and upregulating the expression of pro-inflammatory cytokines,
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chemokines and some mediators such as growth factors and prostaglandins, leading to the
recruitment of immune cells to neoplastic tissue (Colotta et al., 2009). Infiltrated leukocytes
and myeloid cells further deteriorate the status by dramatically increasing the secretion of
inflammatory mediators, resulting cancer-related inflammation. On the other hand,
inflammatory status caused by obesity, infection or other disease through the extrinsic
pathway can also create an inflammatory microenvironment favorable for cancer
progression. Recent studies have pointed out inflammation greatly contributes to tumor
cell growth, angiogenesis, invasion, metastasis, as well as the immunosuppressive effects
responsible for reduced anti-tumor immunity (Mantovani et al., 2008; Allen et al., 2015).

A. camphorata is a medical mushroom with several evidenced biological activities
including anti-inflammatory and anti-cancer effects (Geethangili et al., 2011). AQ and its
derivative, 4-AAQB, have been reported as potent bioactive compounds providing these
health-promoting effects in AC mushroom. The aim of present study is to investigate the
inflammatory status of breast cancer and the potential role of AQ and 4-AAQB as
candidates of CAMs for using in immunotherapy in a MCF-7 breast cancer cell model. In
addition to evaluate the inflammatory mediators related to breast cancer progression, we
included immune checkpoint CD47, aromatase and Wnt signaling in our research targets.
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In our present study, results showed that AQ possessed mild cytotoxicity against MCF-7
breast cancer cells (Figure 6A), which was similar to the effect obtained in the study
conducted by Lee et al. (2015). Furthermore, 4-AAQB treatment exhibited a stronger
growth inhibitory effect compared to AQ treatment against MCF-7 cells (Figure 6A), and
this phenomenon was also evidenced by Chang et al. (2015) that 4-AAQB showed a more
potent growth inhibitory effect against aggressive human colorectal cancer cells. Although
we did not determine the cytotoxicity of AQ and 4-AAQB in normal breast cells. Wang et
al. (2014) indicated that antroquinonol D showed no cytotoxic effect toward MCF-10A
normal mammary gland cells. However, due to the aim of present study was to investigate
the immunomodulatory effects of AQ and 4-AAQB in MCF-7 cells, we thus decided to use
a low concentration of AQ and 4-AAQB possessing relative low cytotoxicity against MCF7 cells as our treatment dosage. On the other hand, since higher levels of TNF-α can be
found in advanced breast cancer patients, the level of TNF-α may also positively correlated
to poor patient outcome (Anderson et al., 2004). However, treatment of TNF-α could
potentially inhibit MCF-7 cell growth even at low concentration, of which’s effect is totally
contrary to the pro-tumor properties mentioned previously (Figure 6B). Specifically to
MCF-7 cells, previous studies had pointed out that TNF-α is responsible for reduced cell
growth by induction of cell apoptosis and inhibition of cell proliferation (Burow et al., 1998;
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Rozen et al., 1998; Lee et al., 2008); however, the inflammatory NF-κB pathway in MCF7 cells after TNF-α treatment remains activated (Machuca et al., 2006). Our results showed
that despite AQ and 4-AAQB could partly abolish the cytotoxic effect of TNF-α (Figure
6B), the inflammatory response induced by TNF-α was still suppressed by cotreatment
with AQ or 4-AAQB (Figure 9F).

Since tumorigenic pathways such as NF-κB and STAT3 are often involved in inflammatory
responses, tumor cells per se are capable of secreting inflammatory mediators. By directly
treatment of AQ or 4-AAQB to MCF-7 cells, expression of IL10 and COX2 (PTGS2) were
significantly suppressed, and TNF expression was also significantly inhibited by the
treatment of 4-AAQB (Figure 7 & 8). Moreover, comparing the inhibitory effects on the
expression of targeted inflammatory mediators between the treatment of AQ and 4-AAQB,
4-AAQB showed a much stronger influence (Figure 7 & 8). Among the suppressed
inflammatory mediators, IL-10 is generally considered as an anti-inflammatory cytokine
that is responsible for the resolution of host inflammatory response and its secretion is
intimately related to inflammatory responses for the purpose of keeping immune
homeostasis (Iyer et al., 2012). However, depending on the context of a microenvironment,
IL-10 could potentially serve as an immunosuppressive factor, especially in a TME.
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Despite the anergy of T cells by IL-10 is profoundly affected in certain condition (Groux
et al., 1996), its crucial effects on M2-like macrophage polarization, reduced antigen
presenting capacity on both macrophages and tumor cells, and inhibited macrophageassociated TH1 immune response may indirectly contribute to the escape of tumor
immunosurveillance (Fiorentino et al., 1991; Moore et al., 2001; Shiratori et al., 2017).
However, in the context of TNF-α induced upregulation of IL10, AQ or 4-AAQB failed to
suppress the elevated expression of IL10 (data not shown). This situation may due to the
complexity of IL10 regulation induced by stimuli (Saraiva et al., 2010), and it is likewise
the same reason for the inconsistent results in COX2 expression after TNF-α stimulation
(data not shown).

In the process of cancer associated inflammation, immune cell infiltration represents the
hallmark in a TME, and macrophages are the most prevalent immune cells among them.
Evidence suggest that in breast tumor tissue, macrophages can occupy more than half of
tumor mass (Obeid et al., 2013). The macrophage recruitment provides the major source
of the secretion of inflammatory mediators. Macrophage colony-stimulating factor (M-CSF,
also known as CSF-1) along with CCL2 are the key molecules triggering macrophage
recruitment to tumor site and activating M2-like macrophage polarization, which is
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responsible for tumor cell growth, enhanced invasion, metastasis and tumor angiogenesis
as well as tumor immunosuppressive capacity (Stewart et al., 2012; Tariq et al., 2017).
However, in our results, data showed that the reduction of the expression of CCL2 after
treatment of AQ or 4-AAQB was failed to achieve statistical significance (Figure 7 & 8),
either in both of the TNF-α and AQ/4-AAQB cotreatment groups compared to TNF-α
treatment group (Figure 9H), and even the expression of CSF1 was significantly increased
up to about 20% after 4-AAQB treatment (Figure 8B). These evidences suggested that the
upregulation of CCL2 is not merely attributed to certain pathway activation, in particular
NF-κB pathway in present study, same situation was involved in the regulation of CSF1
expression. Therefore, it is possible that AQ or 4-AAQB treatment is not able to inhibit the
recruitment of monocytes and macrophages into a breast TME; however, by altering the
inflammatory mediator profile of tumor cells and even the other immune cells and stromal
cells, the recruited macrophages are still likely to maintain their anti-tumor activity (Wang
et al., 2017).

Among the gene expression of 5 inflammatory mediators we aimed to detect in cotreatment
experiment, including IL6, IL10, IFNγ, CCL2, and COX2, only TNF-α induced IL6
upregulation was significantly suppressed by cotreatment of AQ or 4-AAQB (Figure 9F).
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Although treatment of AQ or 4-AAQB to MCF-7 cells failed to significantly reduce the
expression of IL6, the inhibited upregulation of IL6 stimulated by TNF-α treatment in
AQ/4-AAQB cotreatment groups demonstrated that AQ and 4-AAQB are potentially
responsible for the inhibition of TNF-α-induced IL6 upregulation, which was mainly
through the suppression of NF-κB pathway activation. In contrast, the expression level of
IFNγ was further significantly elevated up to 2~3 fold in 4-AAQB and TNF-α cotreatment
group compared to TNF-α treatment group, but not in AQ and TNF-α cotreatment group
(Figure 9G). This IFNγ enhancement phenomenon is also possibly attributed to the
modulatory effect of 4-AAQB on NF-κB pathway. It is evidenced that NF-κB is involved
not only in the production of pro-inflammatory mediators but also in the regulation of antitumor immune response (Yu et al., 2009). NF-κB family consists of five proteins, including
RelA (p65), RelB, c-Rel, p50 and p52, and among them RelA-p50 heterodimer is
considered as prototype NF-κB transcription factor, which is mainly involved in the
regulation of genes encoding oncogenes and pro-inflammatory mediators, such as IL-6, IL1β and COX2; whereas, the other heterodimer c-Rel-p50 is crucial for the expression of
genes related to TH1 immune response, such as IL-12, IFN-γ, CD40 and CD80. Although
a constitutive NF-κB activation is commonly found in cancer cells, a majority of the active
form is RelA-p50. Furthermore, it is strongly suggested that the activation of NF-κB partly
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crosstalk with other transcription factors such as STAT3, by which’s activation could
persistently activate RelA-p50 but reduce c-Rel-p50 (Yu et al., 2009). Nevertheless, the
clear interactions between NF-κB and other signaling still remain to be fully studied.
Therefore, in our results, the reinforced IFNγ expression after TNF-α and 4-AAQB
cotreatment may potentially be via the property of 4-AAQB to interfere with the crosstalk
between NF-κB and the other activated signaling.

As breast cancer can be categorized into ER+ and ER- types, ER+ breast cancer is
profoundly and directly influenced by estrogen, which is able to regulate the mitogenic
signaling through the estrogen receptor (Quigley et al., 2017). However, the pathology of
ER- breast cancer is largely different from ER+ breast cancer, and may greatly attributed to
chronic low-grade inflammation (Amadou et al., 2013). In addition to the pro-tumor
proliferation effect of estrogen, estrogen may still serve as an immunosuppressive factor
by interfering other ER+ stromal cells or immune cells in a TME (Quigley et al., 2017).
Despite estrogen in breast tumor tissue being mainly produced locally by aromatase
enzyme expressed in stromal cells as well as breast cancer cells, previous studies reported
that aromatase expression could be further enhanced by positive feedback from estradiol
and a chronic inflammatory status (Santner et al., 1997; Kinoshita et al., 2003; Morris et
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al., 2011). Indeed, our results showed that TNF-α treatment time-dependently increased the
expression level of aromatase in MCF-7 cells (Figure 10B); whereas AQ and 4-AAQB
treatment inhibited aromatase expression in transcriptional level (Figure 10A).
Interestingly, only TNF-α and 4-AAQB cotreatment successfully suppressed the TNF-αinduced upregulation of aromatase expression (Figure 10C), by which meant that the
mechanisms involved in the inhibitory effect of AQ and 4-AAQB on aromatase expression
are distinct. Since a variety of inflammatory mediators and growth factors (Reed et al.,
1992; Zhao et al., 1995; Zhao et al., 1996; Richards et al., 2003) are reported to be
associated with aromatase expression, the potential molecular mechanisms could be highly
complicated and still remain nuclear. Therefore, our results might only suggest that both
AQ and 4-AAQB potentially are able to inhibit aromatase expression in breast cancer cells,
however, only 4-AAQB is responsible for the suppression of TNF-α-induced aromatase
upregulation.

Besides the connection between inflammation and estrogen mechanisms in breast cancer,
previous review also points out the importance of immune checkpoint and Wnt signaling
responses in an inflammatory breast TME. CD47 as an immune checkpoint is highly
expressed on various tumor cells, including MCF-7 breast cancer cells, compared to
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corresponding normal cells (Willingham et al., 2012; Betancur et al., 2017); however, the
mechanisms responsible for the abnormally upregulation of CD47 expression in cancer
cells are still poorly understood (Betancur et al., 2017). Recently, research have addressed
several transcription factors potentially contributing to the regulation of CD47 expression.
Lo et al. (2015) found that NF-κB could regulate the transcription of CD47 gene by directly
binding to CD47 promoter, and after TNF-α stimulation, the NF-κB binding efﬁciency
increased. Similar results also were reported by Betancur et al. (2017) that NF-κB is
responsible for the activation of CD47 constituent enhancer and promoter, leading to the
upregulation of CD47 in MCF-7 cells, however, the authors also mentioned that even
though NF-κB is a necessary transcription factor for the initiation of CD47 transcription,
only for its binding is far enough to regulate the expression of CD47. The role of NF-κB
in CD47 regulation might partly explain why CD47 expression failed to be enhanced after
TNF-α stimulation (data not shown). Moreover, the possibility that CD47 inhibitory effect
of AQ and 4-AAQB might be counteracted by the elevated NF-κB stimulated by TNF-α
also elucidated the inconsistence in our results that AQ and 4-AAQB lose their ability to
inhibit CD47 expression after cotreatment with TNF-α (data not shown).

In breast cancers, research found that Wnt/β-catenin signaling is activated among ~60% of
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breast carcinomas (Lin et al., 2000). While a less proportion of aberrantly activated Wnt/βcatenin signaling in breast tumors is via somatic mutations directly involved in this
pathway (Yu et al., 2016), extracellular factors might play critical roles in regulating the
activation of this oncogenic pathway. As we mentioned previously, inflammatory
mediators are capable of increasing β-catenin accumulation, leading to advanced breast
cancer development. Specific to the effect of TNF-α on Wnt/β-catenin signaling, our
previous study reported that TNF-α level in breast tissue is positively correlated to the
expression of Wnt targeted gene, JNK1, further, TNF-α treated breast tissues compared to
nontreated control showed a 3-fold higher expression of CCND1 and marginal increased
expression of AXIN2, both of which are well-known Wnt targeted genes (Roubert et al.,
2017). In the present study, Both AQ and 4-AAQB treatment possessed the ability to
suppress C-MYC expression, which is downstream of Wnt/β-catenin signaling (p-values
were 0.052 and 0.001, respectively; Figure 11A). Chang et al. (2015) also pointed out that
after 4-AAQB treatment, the expression levels of Lgr5 and β-catenin were dosedependently inhibited in DLD-1 colorectal cancer cells. However, due to the property that
C-MYC is targeted by multiple signaling pathways in addition to Wnt signaling, hence we
were not able to conclude that the inhibitory effect on C-MYC expression of AQ and 4AAQB was via their ability to interfere Wnt signaling pathway. Next, we treated MCF-7
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cells with TNF-α or TNF-α combined with AQ/4-AAQB and measured the expression
levels of Wnt targeted genes, CCND1, C-MYC and AXIN2. Contrary to our expectation,
TNF-α treatment time-dependently suppressed C-MYC expression and marginally
suppressed CCND1 expression (p for trend values were <0.001 and 0.067, respectively;
Figure 11B). Since previous studies have demonstrated that TNF-α treatment to MCF-7
cells would mitigate cell proliferation and increase cell apoptosis by decreasing the
expression levels of growth factor receptor and estrogen receptor, which are responsible
for tumor cell growth (Rozen et al., 1998; Lee et al., 2008), it is possible that the TNF-α
induced pro-tumor signaling activation, such as NF-κB and Wnt pathways, in MCF-7 cells
fail to counteract or overcome the anti-proliferation and pro-apoptosis effects; therefore,
C-MYC and CCND1 expression, which profoundly mediate cell proliferation, are
suppressed in MCF-7 cells after TNF-α treatment. Furthermore, our data showed that TNFα and AQ cotreatment exerted stronger inhibition on C-MYC expression compared to 4
hours TNF-α treatment or TNF-α and 4-AAQB cotreatment (p-values were 0.008 and
0.0003, respectively; Figure 11C). On the other hand, AXIN2 expression marginally
increased by 1.2-fold higher after 3 hours of TNF-α treatment (p-value was 0.088; data not
shown), and cotreatment of TNF-α and AQ successfully inhibited this elevated AXIN2
expression (p-value was 0.047; data not shown). Taken together, these data suggested that
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AQ compared to 4-AAQB exerted a much powerful inhibitory effect on TNF-α induced
Wnt signaling responses.

Overall, our results thus do suggest that AQ and 4-AAQB derived from AC mushroom
possess the function to modulate the expression of inflammatory mediators potentially
responsible for generating a chronic inflammatory breast TME in MCF-7 cells. Moreover,
it seems to support our hypothesis that AQ and/or 4-AAQB both are potential compounds
for inhibiting aromatase and CD47 expression. However, consider to Wnt signaling
responses, only AQ showed an effective inhibition on TNF-α induced upregulation of Wnt
targeted genes. Compare these two compounds, 4-AAQB seems to hold a much powerful
modulatory effects on the expression of inflammatory mediators, aromatase as well as
CD47, whereas, AQ may be a much effective inhibitory compound for Wnt signaling
responses. Several limitation should be taken into account while interpreting our results. 1)
Only one stimulus, TNF-α, was included in the present study. 2) Relative higher TNF-α
concentration used in treatment, since TNF-α levels in serum or breast tissue are generally
in the pg/mL range. 3) The levels of secreted inflammatory mediators were not measured.
4) Activation levels of targeted pathways, including NF-κB and Wnt signaling, were not
measured. 5) Experiments were only conducted in breast cancer cells, hence the effects on
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stromal cells or immune cells and their interaction with cancer cells remain unclear. In
order to more clearly understand the role of AQ and 4-AAQB in treating breast cancer
through their immunomodulatory effects, further experiments should be conducted. For
instance, measuring NF-κB and Wnt signaling active levels before and after treatment to
clarify the actual mechanisms and designing a co-culture model to better explore the
influence between cancer cells and other cells. Eventually, experimenting on an animal
model to thoroughly understand their effects on breast cancer in the context of an intact
breast TME. Nevertheless, our results provided promising evidence that AQ and/or 4AAQB derived from AC mushroom may influence the development of breast cancer via
the modulation of inflammatory mediators and inflammation-driven upregulation of
aromatase as well as Wnt signaling.
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APPENDIX A
TABLE OF PERFORMED ASSAYS AND EXPERIMENTAL DESIGN
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Experiment

Cell line

MTT Assay 1

Design

Dosage

Time

Control group (non-treatment)

-

24 & 48 hours

Experimental AQ treatment
group
4-AAQB treatment

0~50 μM

Control group (non-treatment)

-

0~50 μM

TNF-α treatment
TNF-α + AQ
Experimental
treatment
group
TNF-α + 4-AAQB

MTT Assay 2

treatment

MCF-7

TNF-α: 0~10 ng/mL
TNF-α: 0~10 ng/mL

AQ: value based on
MTT assay 1
on MTT assay 1

Experimental AQ treatment
group
4-AAQB treatment

Value based on MTT assay 1

Control group (non-treatment)

-

Value based on MTT assay 1

TNF-α treatment

group

24 hours

4-AAQB: value based
-

Experimental

24 hours

0~10 ng/mL

Control group (non-treatment)

Gene
Expression
Analysis

24 & 48 hours

24 hours
24 hours
0.5, 1, 2, 3, 4 hours

Value based on MTT assay 2

TNF-α + AQ

TNF-α: value based

AQ: value based on

treatment

on MTT assay 2

MTT assay 1

TNF-α + 4-AAQB
treatment

TNF-α: value based
on MTT assay 2

4-AAQB: value based
on MTT assay 1

Table 1. Experimental design
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0.5, 1, 2, 3, 4 hours

APPENDIX B
TABLE OF PRIMERS USED FOR REAL-TIME PCR ANALYSIS
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Pathway

Cancer-related
inflammation

Genes

Aromatase

Reverse Primer

IL6

ACTCACCTCTTCAGAACGAATTG

CCATCTTTGGAAGGTTCAGGTTG

IL10

GACTTTAAGGGTTACCTGGGTTG

TCACATGCGCCTTGATGTCTG

IL1β

ATGATGGCTTATTACAGTGGCAA

GTCGGAGATTCGTAGCTGGA

IFNγ

TCGGTAACTGACTTGAATGTCCA

TCGCTTCCCTGTTTTAGCTGC

TNF

CCTCTCTCTAATCAGCCCTCTG

GAGGACCTGGGAGTAGATGAG

TGFβ1

GGCCAGATCCTGTCCAAGC

GTGGGTTTCCACCATTAGCAC

PTGS2

CTGGCGCTCAGCCATACAG

CGCACTTATACTGGTCAAATCCC

CCL2

CAGCCAGATGCAATCAATGCC

TGGAATCCTGAACCCACTTCT

CSF1

TGGCGAGCAGGAGTATCAC

AGGTCTCCATCTGACTGTCAAT

CCND1

GCTGCGAAGTGGAAACCATC

CCTCCTTCTGCACACATTTGAA

GGCTCCTGGCAAAAGGTCA

CTGCGTAGTTGTGCTGATGT

AXIN2

CAACACCAGGCGGAACGAA

GCCCAATAAGGAGTGTAAGGACT

CD47

AGAAGGTGAAACGATCATCGAGC

CTCATCCATACCACCGGATCT

CYP19A1

TGGAAATGCTGAACCCGATAC

AATTCCCATGCAGTAGCCAGG

GAPDH

GGAGCGAGATCCCTCCAAAAT

GGCTGTTGTCATACTTCTCATGG

Wnt-signaling pathway C-MYC
Immune checkpoint

Forward Primer

Table 2. Primers of targeted genes and GAPDH
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